Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ,
Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE,
Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA,
Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nature
Medicine 2002; 8(2):121-127.
Berry DA. The utility of mammography for women 40 to 50 years of age (con). In:
Devita VT, Hellman S, Rosenberg SA, editors. Progress in Oncology. Sudbury, MA: Jones and Bartlett;
2002. p. 233-259.
Berry DA. Clinical trial design. In: Bast R, et al., editors. Helene Harris Memorial
Trust Conference Proceedings. (To appear, 2002)
Berry DA. Adaptive clinical trials and Bayesian statistics (with discussion).
Accepted for publication in Pharmaceutical Report, by the American Statistical Association, 2002.
Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J,
Stadtmauer E, Costanza M, Freytes CO, Gale RP,
Henderson IC, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC,
Rowlings P, Spitzer G, Horowitz MM.
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of the Cancer and
Leukemia Group B trials with data from the Autologous Bone Marrow Transplant Registry.
Journal of Clinical Oncology 2002; 20(3):743-750.
Berry DA, Iversen E, Gudbjartsson DF, Hiller E, Garber J, Peshkin B, Lerman C,
Watson P, Lynch H, Hilsenbeck S, Rubinstein W, Hughes K, Parmigiani G.
Validation of BRCAPRO, sensitivity testing of BRCA1 and BRCA2, and implications
for the prevalence of other breast cancer susceptibility genes. Accepted for publication
in the Journal of Clinical Oncology, 2002.
Berry DA, Seltzer JD, Xie C, Wright DL, Smith JSC. Assessing probability of ancestry
using simple sequence repeat profiles: applications to maize hybrides and inbreds.
Accepted for publication in Genetics, 2002.
Cheung YK, Thall PF. Monitoring the rates of composite events with censored data in phase II clinical trials.
Biometrics 2002; 58(1):89-97.
Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm
EA. Loss of MDA-7 expression with progression of melanoma. Journal of Clinical
Oncology 2002; 20(4):1069-1074.
Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures
in the science and art of treatment choices. Supportive Care in Cancer 2002; 10(3):189-196.
Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
Annals of Oncology 2002; 13(1):125-134.
Fuller GN, Hess KR,Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W.
Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene
expression profiles parallels morphology-based classification, correlates with
survival, and reveals clinically-relevant novel glioma subsets.
Brain Pathology 2002; 12(1):108-116.
Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson IC,
Norton L, Hayes DF. Association of angiogenesis and disease outcome in node-positive breast
cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer
and Leukemia Group B correlative study from protocols 8541/8869. Journal of Clinical Oncology 2002; 20(3):732-742.
Jeha S, Smith FO, Estey E, Shen Y, Liu D, Manshouri T, Albitar M. Comparison between
pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2)
protein levels. Leuk Res 2002; 26(4):399-402.
Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M, Maushouri T, Quackenbuch RC,
Keating M, Albitar M. Clinical significance of plasma endostatin in acute myeloid
leukemia/myelodysplastic syndrome. Cancer 2002; 94(1):14-17.
Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model
of oral tongue squamous cell carcinoma. Clinical Cancer Research 2002; 8(1):293-298.
Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M,
Kwari MI, Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia:
a retrospective analysis of 213 patients. Blood 2002; 99(3):840-849.
Pecora A, Lazarus H, Stadtmauer E, Winter J, Van Vilet A, Berry D, Gray R, Jennis A,
Goldberg S, Cooper B, Preti R. Role of induction with high dose chemotherapy in autologous
stem cell transplant for metastatic breast cancer. Accepted for publication in Bone Marrow
Transplantation, 2002.
Petros WP, Broadwater G, Berry DA, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP,
Colvin MO, Peters WP. Association of high-dose cyclophosphamide, cisplatin and carmustine
pharmacokinetics with response, toxicity and dosing weight in patients with primary breast cancer.
Accepted for publication in Clinical Cancer Research, 2002.
Porter GA, Cantor SB, Ahmad SA, Lenert JT, Ballo MT, Hunt KK, Feig BW, Patel SR,
Benjamin RS, Pollock RE, Pisters PW. Cost-effectiveness of staging computed tomography of
the chest in patients with T2 soft tissue sarcomas. Cancer 2002; 94(1):197-204.
Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Alfred Yung WK, Levin VA. Phase II
trial of Temozolomide plus the matrix metalloproteinase inhibitor, Marimastat,
in recurrent and progressive glioblastoma multiforme.
Journal of Clinical Oncology 2002; 20(5):1383-1388.
Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP,Adams DJ,
Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H, Moore JO.
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or
refractory acute leukemia. Journal of Clinical Oncology 2002; 20(3):674-679.
Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, Do KA, Sinicrope FA.
A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin
E(2) levels as a biomarker. Cancer Epidemiology, Biomarkers and Prevention 2002; 11(3):275-279.
Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L,
Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM.
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced
squamous skin cancer. J Clin Oncol 2002; 20(2):364-70.
Shureiqi I, Cantor SB, Lippmann SM, Brenner DE, Chernew ME, Fendrick AM. Clinical
and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.
British Journal of Cancer 2002; 86(2):226-232.
Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF Jr, Smith TL, Williams D, Logothetis CJ.
Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
J Clin Oncol 2002; 20(5):1361-1367.
Skinner CS, Schildkraut J, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer E,
Iglehart JD, Futreal PA, Rimer BK. Tailored versus non-tailored materials to facilitate
BRCA testing decisions. Accepted for publication in Genetic Testing, 2002.
Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM,
Regimbeau JM, Rashid A, Cleary KR, Nagorney DM. Simplified staging for hepatocellular carcinoma.
Journal of Clinical Oncology 2002; 20(6):1527-1536.
Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, Lerut J, Materne R,
Wang X, Encarnacion A, Herron D, Mathey C, Ferrari G, Charnsangavej C, Do KA, Denys A.
Body surface area and body weight predict total liver volume in Western adults.
Liver Transplantation 2002; 8(3):233-240.
Wang XS, Giralt SA, Mendoza TR, Engstrom MC, Johnson BA, Peterson N, Broemeling LD,
Cleeland CS. Clinical factors associated with cancer-related fatigue in patients being treated
for leukemia and non-Hodgkin's Lymphoma. Journal of Clinical Oncology 2002; 20(5):1319-1328.
2001
Arrington JL, Chapkin RS, Switzer KC, Morris JS,
McMurray DN. Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell
subset activation. Clin Exper Immunol 2001; 125(3):499-507.
Baggerly KA, Coombes KR, Hess KR, Stivers DN, Abruzzo LV, Zhang W.
Identifying differentially expressed genes in cDNA microarray experiments. Journal of Computational Biology 2001; 8(6):639-659.
Berry DA. Role of population-based studies in assessing genetic cancer risk.
J Natl Cancer Inst 2001; 93(16):1188-1189.
Chang DW, Langstein HN, Coupla A, DeMonte F, Do K-A, Wang X, Robb G. Reconstructive management
of Cranial base defects following tumor ablation. Plast Reconstr Surg 2001; 107(6):1346-1355, discussion 1356-1357.
Cheng Y, Su F, Berry DA. Group sequential strategies in two-armed bandit problems:
Implications for clinical trial sample size. Ann Statistics. In press.
Elting LS, Rubenstein EB, Kurtin D, Martin CG, Rodriguez S, Cantor SB,
Laiho E, Kanesan K, Benjamin RS. Incidence, cost, and outcomes of bleeding and chemotherapy dose
modification among solid tumor patients with chemotherapy-induced thrombocytopenia.
J Clin Oncol 2001; 19(4):1137-1146.
Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients
with papillary thyroid cancer: a decision analysis. Surgery 2001; 130(6):921-930.
Estey E, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M.
Comparison of idarubicin + ara-C, fludarabine + ara-C,and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia,
refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001; 98(13):3575-3583.
Fleming JB, Cantor SB, Varma DG, Holst D, Feig BW, Hunt KK, Patel SR, Benjamin RS,
Pollock RE, Pisters PW. Utility of chest computed tomography for staging in patients with T1
extremity soft tissue sarcomas. Cancer 2001; 92(4):863.868.
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D,
Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M,
Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative
regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing
allogeneic progenitor cell transplantation. Blood 2001; 97(3):631-637.
Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO Jr, Ramakrisha P,
Rosner GL, Hodge JP, O'Brien S, Keating MJ. J Clin Oncol 2001; 19(8):2142-2152.
Gutman H, Hess KR, Kokotsakis JA, Ross MI, Guinee VF, Balch CM. Surgery for abdominal metastases of
cutaneous melanoma. World J Surg 2001; 25(6):750-758.
Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB,
Berry DA, Vredenburgh JJ, Rizzeria D, Bentley RC. Comparison of methods of measuring HER2 in metastatic
breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001; 19(6):1698-1706.
Hess KR , Zhang W, Baggerly KA , Stivers DN, Coombes KR. Microarrays:
handling the deluge of data and extracting reliable information. Trends in Biotechnology 2001; 19(11):463-468.
Hickey K, Do K-A, Green A. Smoking and prostate cancer.
Epidemiolog Rev 2001; 23(1):115-125. Review.
Ibrahim S, Keating M, Do K-A, O'Brien S, Lerner S, Mun YJ, Huh Y, Jilani I, Kantarjian HM. CD38 expression
as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98(1):181-186.
Kantarjian HM, Shan J, Smith T, Talpaz M, Kozuch P, Rios MB, Cortes J, Giles FJ,
O'Brien S. Response to therapy is independently associated with survival prolongation in
chronic myelogenous leukemia in the blastic phase. Cancer 2001; 92(10):2501-2507.
Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE,
Chamberlain RM, Williams B, Pajak TF, Goepfert H, Hong WK. The impact of smoking status, disease
stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head
and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001; 10(8):823-829.
Khuri FR, Lee JS, Lippman SM, Lee JJ, Kalapurakal S, Yu R, Ro JY, Morice RC, Hong WK, Hittelman WN.
Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. Cancer Epidemiol Biomarkers
Prev 2001 10(4):311-318.
Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM. Design considerations for efficient prostate
cancer chemoprevention trials. Urology 2001; 57(4 Suppl 1):205-212.
Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer
chemoprevention trials. Urology 2001; 57(4 Suppl 1):205-212.
Lee JJ, Liu D, Lee JS, Kurie JM, Khuri FR, Ibarguen H, Morice RC, Walsh G, Ro JY,
Broxson A, Hong WK, Hittelman WN. Long-term impact of smoking on lung epithelial proliferation in
current and former smokers. J Natl Cancer Inst 2001; 93(14):1081-1088.
Lee JJ, Tseng C. Uniform power method for sample size calculatin in historical control
studies with binary response. Control Clin Trials 2001; 22(4):390-400.
Levin RJ, Berry DA, Cryer H, Fost N, Houghton J, Krome R, Washington G, Bechhofer R, Cook T, Fisher M. Monitoring
a clinical trial conducted under the new FDA regulations allowing a waiver of prospective informed consent. Ann
Emergency Med. In press.
Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, WIlding G, Partin AW, Lee JJ,
Lippman SM. Executive summary of the National Cancer Institute Workshop: highlights and recommendations.
Urology 2001; 57 (4 Suppl 1):4-27.
Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W,
Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK.
Randomized phase III intergroup trial of isotretinoin to prevent second primary
tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93(8):605-618.
Mielke CH, Shields JP, Broemeling LD. Coronary artery calcium,
coronary artery disease, and diabetes. Diabetes Research and Clinical
Practice 2001; 53(1):55-61.
Mielke CH, Shields JP, Broemeling LD. Risk factors and coronary
artery disease for asymptomatic women using electron beam computed
tomography. Journal of Cardiovascular Risk 2001; 8(2):81-86.
Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong MY, Caroll RJ. Parametric and nonparametric
methods for understanding the relationship between carcinogen-induced DNA adduct levels in distal and proximal
regions of the colon. J Am Stat Assoc. In press.
Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong MY, Carroll RJ. Understanding the relationship
between carcinogen-induced DNA adduct levels in distal and proximal regions of the colon. Math Models in Exper
Nutr. Novotny J, Green M, Boston RC, eds. Plenum NY. In press.
Müller P, Rosner GL, Inoue LYT, Dewhirst MW. A Bayesian model for detecting acute change in
nonlinear profiles. Journal of the American Statistical Association 2001; 96:1215-1222.
Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM.
Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival.
Int J Oncol 2001; 17(5):963-969.
Ramdas L, Coombes KR, Baggerly K, Abruzzo L, Highsmith WE, Krogmann T,
Hamilton SR, Zhang W. Sources of nonlinearity in cDNA microarray expression measurements.
Genome Biology 2001 ;2(11):Research0047.
Shen Y, Cai J. Maximum of the weighted Kaplan-Meier tests with application to cancer prevention
and screening trials. Biometrics, in press.
Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection
clinical trials: mammograms and physical examination. J Clin Oncol 2001; 19(15):3490-3499.
Shin DM, Charuruks N, Lippman SM, Lee JJ, Ro JY, Hong WK, Hittelman WN. p53 protein accumulation and
genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 2001; 10(6):603-609.
Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ,
Ang KK, Lippman SM, Hong Wk. Phase II study of paclitaxel, ifosfamide, and carboplatine in patients
with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001; 91(7):1316-1323.
Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippmann SM. Nonsteroidal
anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1
expression. Cancer Res 2001; 61(12):4879-4884.
Soria JC, Moon C, Wang L, Hittelman WN, Jang SJ, Sun SY, Lee JJ, Liu D,
Kurie JM, Morice RC, Lee JS, Hong WK, Mao L. Effects of N-(4-hydroxyphenyl)retinamide
on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 2001; 93(16):1257-1263.
Staniswalis JG, Thall PF. An explanation of generalized profile likelihoods.
Stat Comput 2001;11:293-398.
Taylor E, Cogdell D, Coombes K, Hu L, Ramdas L, Tabor A, Hamilton S, Zhang W.
Sequence verification as quality-control step for production of cDNA microarrays.
Biotechniques 2001; 31(1):62-65.
Thall PF. Bayesian clinical trial design: the Willie Sutton approach. Chance 2001; 14:23-28.
Thall PF, Cheng SC. Optimal two-stage designs for clinical trials based on safety and efficacy. Stat Med.
Stat Med 2001; 20(7):1023-1032..
Tseng J, Glisson B, Khuri F, Shin D, Myers J, El-Naggar A, Roach J, Ginsberg L,
Thall PF, Wang X, Teddy S, Lawhorn K, Zentgraf R, Steinhaus G, Abbruzzese J, Hong WK,
Herbst R. Phase II study of the anti-angiogenesis agent thalidomide in recurrent or metastatic
squamous cell carcinoma of the head and neck. Cancer 2001; 92(9):2364-2373.
Yang L-Y, Lan L, Jiang H, Shen Y, and Plunkett W.
Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated
cytotoxic synergism with cisplatin in human colon tumor cells
defective in mismatch repair but proficient in nucleotide excision
repair. Clin Cancer Res, in press.
Zhang W, Laborde PM, Coombes KR, Berry DA, Hamilton SR.
Cancer genomics: promises and complexities. Clin Cancer Res 2001; 7(8):2159-2167.
2000
Alexanian R, Weber D, Dimopoulos M, De la salle K, Smith TL. Randomized trial of Interferon or dexamethasone
as maintenance treatment for multiple myeloma. Am J Hematol 2000;65:204-209.
Anscher MS, Lee C, Hurwitz H, Tyler D, Prosnitz LR, Jowell P, Rosner G, Samulski T, Dewhirst MW.
A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia and external beam
radiotherapy for treatment of locally advanced, unressectable or recurrent rectal cancer.
Int J Radiat Oncol Biol Phys 2000;47(3):719-724.
Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L.
Her-2/neu and p53 expression vs tamoxifen resistance in estrogen-receptor-positive node-positive breast cancer.
J Clin Oncol 2000;18(20):3471-3479.
Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, Lee JJ, Kellems RE.
Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis,
pulmonary inflammation and airway obstruction. J Exp Med 2000;192(2):159-170.
Blackwell K, Haroon Z, Broadwater G, Berry DA, Harris L, Iglehard JD, Dewshirt M, Greenberg C.
Plasma D-dimer levels in operable breast cancer.
Patients correlate with clinical stage and axillary lymph node status.
J Clin Oncol 2000;18(3):600-608.
Broemeling LD. A Bayesian analysis for spatial processes with application to
disease mapping. Statistics in Medicine 2000; 19(7):957-974.
Cai J Shen Y. Permutation tests for comparing marginal
survival functions with clustered failure time data. Stat Med 2000;19(21):2963-2973.
Davidson LA, Brown RE, Chang W-CL, Lupton JR, Morris JS, Wang N, Carrol RJ, Turner ND, Chapkin RS.
Morphodensitometric analysis of protein kinase C B-II expression in the rat colon: modulation by
diet and relation to in situ cell proliferation and apoptosis. Carcinogenesis 2000;21:1513-1519.
Do K-A, Broom BM, Kuhnert P, Duffy DL, Todorov AA, Treloar SA, Martin NG. Genetic analysis
of the age at menopause by using estimating equations and
Bayesian random effects models. Stat Med 2000;19(9):1217-1235.
Do K-A, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Longitudinal study of risk factors
for coronary heart disease across the menopausal transition. Am J Epidemiol 2000;151(6):584-593.
Dougherty TB, Porsche VH, Thall PF. Maximum tolerated dose of
nalmefene in patients receiving epidural fentanyl and dilute
bupivaccine for postoperative analgesia. Anesthesiol 2000; 92(4):1010-1016.
Estey E, Shen Y, Thall, PF. Effect of time to complete remission
on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.
Blood 2000;95(1):72-77.
Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM.
Troxacitabin, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
J Clin Oncology 2000;19(3):762-771.
Grimm EA, Smid CM, Lee JJ, Tseng C-H, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma
patients during sequential biochemotherapy. Clin Can Res 2000;6:3895-3903.
Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF.
Association of angiogenesis in lymph node metastases with outcome of breast cancer.
J Natl Cancer Inst 2000;92(6):486-492.
Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ.
Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with
stage I non-small cell lung carcinoma. Clin Cancer Res 2000;6(3):790-797.
Hong MY, Lupton JR, Morris JS, Wang N, Carroll RJ, Davidson LA, Elder R, Chapkin RS. Dietary fish
oil reduces O-6-methylguanine DNA adduct levels in the rat colon in part by increasing apoptosis during
tumor initiation. Cancer Epidem Biomarkers Prevent 2000;9:819-826.
Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B,
Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB,
Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast
carcinoma. J Natl Cancer Inst 2000;92(3):225-233.
Huh YO, Smith TL, Collins P, Bueso-Ramos C, Albitar M, Kantarjian HM, Pierce SA, Freireich EJ. Terminal
deoxynucleotidyl transferase expression acute myelogenous leukemia and myelodysplasia as determined by flow
cytometry. Leuk Lymph 2000;37(3-4):319-331.
Iversen ES Jr, Parmigiani G, Berry DA, Schildkraut JM. Genetic susceptibility and survival: Application to
breast cancer. J Am Stat Assoc 2000;95:28-42.
Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M,
Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive
regimen in adult acute lymphocytic leukemia. J Clin Oncol 2000;18(3):547-561.
Keating MJ, Smith TL, Lerner S, O'Brien S, Robertson LE, Kantarjian H, Freireich EJ. Prediction of
prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymph 2000;
37(1-2):71-85.
Lee JJ, Hess KR, Dubin JA. Extensions and applications of event charts. Am Stat 2000;
54:63-10.
Khuri FR, Lotan R, Kemp BL, Lippman SM, Hong W, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, Walsh GL,
Lee JS, Hong WK, Xu X-C. Retinoic acid receptor-Β as a prognostic indicator in stage I non-small cell
lung cancer. J Clin Oncol 2000;18:2798-2804.
Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsho GL, Broxson A, Lippman SM, Ro JY, Kemp BL,
Liu D, Fritsche HA, Zu XC, Lotan R, Hong WK. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous
metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000;6:2973-2979.
Lee JJ, Hess KR, Dubin JA. Extensions and applications of event charts. Am Stat 2000;54:63-70.
Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS,
Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM.
Predicting cancer development in oral leukoplakia: Ten years of translational research.
Clin Cancer Res 2000;6(5):1702-1710.
Meyers CA, Hess KR, Yung Wk, Levin VA. Cognitive function as a predictor of survival
in patients with recurrent malignant glioma. J Clin Oncol 2000;18(3):646-650.
Meric F, Milas M, Hunt KK, Hess KR, Pisters PW, Hildebrandt G, Patel SR, Benjamin RS, Plager C,
Papadopolous NE, Burgess MA, Pollock RE, Geig BW. Impact of neoadjuvant chemotherapy on postoperative morbidity
in soft tissue sarcomas. J Clin Oncol 2000; 18(19):3378-3383.
Myers CA, Hess KR, Yung WKA, Levin VA. Cognitive function as a predictor of survival in patients with
recurrent malignant glioma. J Clin Oncol 2000;18:646-650.
Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F,
Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KMW, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J.
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer.
J Clin Oncol 2000;18(3):690-622.
Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach SC, Antolak JA, Starkschall G, Rosen I.
Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate
cancer. J Clin Oncol 2000;18:3904-3911.
Rodriguez J, Cortes J, Talpaz M, O'Brien S, Smith TL, Rios MB, Kantarjian H. Serum beta-2 microglobulin levels
are a significant prognostic factor in Philadelphia chromosome-positive chornic myelogenous leukemia.
Clin Cancer Res 2000;6(1):147-152.
Ryan PA, Do K-A, Kay BH. Definition of Ross River virus vectors at Maroochy Shire, Australia.
J Entomol 2000;37:146-152.
Seong CM, Giral S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall PF, Siciliano MJ, Champlin RE.
Early detection of relapse by hypermetaphase fluoresence in situ hybridization after allogeneic bone marrow transplantation
for chronic myeloid leukemia. J Clin Oncol 2000;18(9):1831-1836.
Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK.
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression.
J Natl Cancer Inst 2000;92(1):69-73.
Shureiqi I, Chan D, Lee JJ, Yang P, newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM. 15-LOX-1:
a novel molecular target for non-steroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells.
J Natl Cancer Inst 2000;92:1136-1142.
Stangl DK, Berry DA. Meta-analysis: past and present challenges. In Meta-Analysis in Medicine and Health
Policy. pgs 1-28. Stangl DK, Berry DA, eds. New York: Marcel Dekker, 2000.
Steinbach G, Lynch PM, Phillips MH, Wallace EH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, et al.
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
N Engl J Med 2000;342(26):1946-1952.
Tae K, El-Naggar A, Yoo E, Feng L, Lee JJ, Hong WK, Hittelman WN, Shin DM. Expression of vascular endothelial
growth factor (VEGF) and microvessel density in head and neck tumorigenesis. Cancer Res 2000;6:2821-2828.
Tang X, Khuri F, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. Hypermethylation of the DAP-kinase CpG island
correlates with aggressive biological behavior in stage I non-small cell lung cancer. J Natl Cancer Inst 2000;
92:1511-1516.
Tengs TO, Berry DA. The cost-effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility
genes. Dis Mgmt Clin Outcomes 2000;winter:15-24.
Thall PF, Millikan R, Sung H-G. Evaluating multiple
treatment courses in clinical trials. Stat Med 2000;19(8):1011-1028.
Thall PF, Simon R, Shen Y. Approximate Bayesian
evaluation of multiple treatment effects. Biometrics 2000;56(1):213-219.
Treloar SA, Sadrzadeh S, Do K-A, Martin NG, Lambalk CB. Birth weight and age at menopause in Australian female twin pairs:
Exploration of the fetal origin hypothesis. Hum Reprod 2000;15(1):55-59.
Tu SM, Millikan R, Mengistu B, Delpassand E, Amato R, Pagilaro L, Daliani D, Papandreou C, Smith TL,
Kim J, Podoloff D, Logothetis C. Bone-targeted therapy for advanced androgen-independent carcinoma of the
prostate: a randomized phase II trial. Lancet 2000;127:512-519.
Vauthey JN, Chaoui A, Do K-A, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G,
Hawkins IF, Caridi J. Standardized measurement of the future liver remnant prior to extended liver resection: methodology
and clinical associations. Surg 2000;127(5):512-519.
Vernook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Johl R, Budman D, Meropol NJ,
Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction:
Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18(14):2780-2787.
Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. The topoisomerase I inhibitor DX-89651f is
active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res
2000;6:731-736.
Yang L-Y, Lan L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogtes gemcitabine-
mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient
in necleotide excision repair. Clin Cancer Res 2000;6:773-781.
Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS,
Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R,
Pisters KM, Putnam JB Jr, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses to
adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type
p53 (Ad-p53). Cancer Gene Ther 2000;7(4):530-536.
Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, Mao L. Prognostic implication of microsatellite
alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6(2):559-565.
Zhou X, Tan FK, Stivers DN, Arnett FC. Microsatellites and intragenic polymorphisms of transforming growth
factor beta and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (scleroderma):
A preliminary analysis showing no genetic association. Arthritis Rheum 2000;43(5):1068-1073.
1999
Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L.
Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and Leukemia Group B phase III study 8741.
J Clin Oncol 1999;17(1):64-73.
Albitar M, Dong Q, Saunder D, Lucas L, Kaabi L, Zaldivar E, and
Thall PF. Evaluation of automated leukocyte differential
counts in a cancer center. Lab Hematol 1999;5:10-14.
Ayoub JP, Palmer JL, Huh Y, Cabanillas F, and Younges A.
Therapeutic and prognostic implications of peripheral blood
lymphopenia in patients with Hodgkin's Disease. Leukemia
Lymphoma 1999;34:519-527.
Bell BS, Broemeling LD. A Bayesian analysis for spatial processes with application to disease mapping.
Stat Med 1999;19(7):957-974.
Bellamy N, Klestov A, Muirden K, Kuhnert P, Do K-A, O'Gorman L, Martin N.
Perceptual variation in categorizing individuals according to American College of Rheumatology classification criteria
for hand, knee and hip osteoarthritis: Observations based on an Australian twin registry
study of OA. J Rheum 1999;26(12):2654-2658.
Bellamy N, Tesar P, Walker D, Klestov A, Muirden K, Kuhnert P, Do K-A, O'Gorman L, Martin N. Perceptual variation
in grading hand, hip and knee radiographs: Observations based on an Australian twin registry study of osteoarthritis.
Ann Rheum Dis 1999:58(12):766-769.
Berry DA, Budman DR. Response: re:dose and dose intensity as determinants of outcome in the adjuvant treatment
of breast cancer. J Natl Cancer Inst 1999;91(16):1425A-1425.
Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP.
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
J Clin Oncol 1999;17(3):1040-1046.
Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA,
Jennings M, McConkey DJ, Corazon D, Bucana CD, Cleary KR, Chiao PJ,
Abruzzese JL, and Evans DB. Prognostic
factors in resectable pancreatic cancer:p53 and bcl-2.
J Gastroint Surg 1999;3(3):263-277.
Brandt ER, Hayman WA, Currie B, Carapetis J, Jackson DC, Do K-A, Good MF.
Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A
streptococci from Australian Aboriginal endemic communities. Int Immunol 1999;11(4):569-576.
Broemeling LD, Gregurich MA [letter]. Confidence intervals for differences in correlated binary proportions.
Stat Med 1999;18(1):109.
Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V,
Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau, SW,
McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective
evaluation of paclitaxel versus combination chemotherapy with
fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant
therapy in patients with operable breast cancer. J Clin
Oncol 1999;17(11):3412-3417.
Chakraborty R, Stivers DN, Su B, Zhong Y, Budowle B [review]. The utility of short tandem repeat
loci beyond human identification: Implications for development of new DNA typing systems.
Electrophoresis 1999;20(8):1682-1696.
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E III, McIntyre OR,
Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination
chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study--Cancer and Leukemia Group
B 8642. J Clin Oncol 1999;17(5):1397-1406.
Do K-A, Kirk K. Discriminant analysis of event-related potential curves using smoothed principal
components. Biometrics 1999;55:174-181.
Estey E, Thall PF, Pierce S. Randomized phase II study of
fludarabine + cytosine arabinoside + idarubicin +/- all trans
retinoic acid +/- granulocyte-colony stimulating factor in poor
prognosis newly-diagnosed acute myeloid leukemia and myelodysplastic
syndrome. Blood 1999;93(8):2478-2484.
Estey EH, Thall PF, Reed P, Dong Q, Kantarjian H, Pierce S,
Keating M. Treatment of newly-diagnosed AML, RAEB-t or RAEB with
lisofylline or placebo in addition to chemotherapy. Leukemia 1999;13(6):850-854.
Faderl S, Thall PF, Kantarjian HM, Talpaz M, Pierce S, Harris
D, Van Q, Estrov Z. Caspase 2 and caspase 3 as predictors of complete
remission and survival in adults with acute
lymphoblastic leukemia. Clin Cancer Res 1999;5(12):4041-4047.
Fuller GN, Rhee CH, Hess KR, Caskey L, Wang R, Bruner JM,
Yung WKA, Zhang W. Reactivation of insulin-like growth factor
binding protein 2 expression in glioblastoma multiforme: a revelation
by parallel gene expression profiling. Cancer Res 1999;59(17):4228-4232.
Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ,
Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial
of intravenous melphalan, paclitaxel and cisplatin plus
granulocyte-colony stimulating factor in patients with suboptimal
advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Cancer 1999;86(11):2291-2300.
Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH,
Lee JJ, Balch CM, Reintegen DS, Ross MI. Multi-institutional
melanoma lymphatic mapping experience: The prognostic value of
sentinel lymph node status in 612 stage I or II melanoma patients.
J Clin Oncol 1999;17(3):976-983.
Groves MD, Maor MH, Meyerss C, Kyritsis AP, Jaeckle KA, Yung WkA,
Sawaya Re, Hess KR, Bruner JM, Peterson P, Levin VA.
A phase II trial of high-dose bromodeoxyuridine with accelerated
fractionation radiotherapy followed by procarbazine, lomustine, and
vincristine for glioblastoma multiforme. Intl J Radiat Oncol Biol Phys 1999;45:127-135.
Ha CS, Kavadi V, Dimpopulos MA, Hagemeister FB, Osborne BM,
Fuller LM, Smith TL, Hess MA, McLaughlin PW, Cabanilas FF,
and Cox JD. Hodgkin's disease with lymphocyte predominance:
Long-term results based on current histopathologic criteria.
Int J Radiat Oncol Biol Phys 1999;43(2):329-334.
Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas [review].
J Neurooncol 1999;42(3):227-231.
Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL.
Classification and regression tree analysis of 1,000 consecutive
patients with unknown primary carcinoma. Clin Cancer Res 1999;5(11):3403-3410.
Hess KR, Serachitopol Dm, Brown BW. Hazard function
estimators: a simulation study. Stat Med 1999;18(22):3075-3088.
Hess KR, Wong Et, Jaeckle KA, Kyritsis AP, Levin VA,
Prados MD, and Yung WKA. Response and progression in recurrent
malignant glioma. Neuro-Oncol 1999;1:282-288.
Hill LR, Hess KR, Stephens LC, Tinkey PT, and Price RE.
Comparison of kidney weight and volume to selected anatomical
parameters in the adult female rhesus monkey (Macaca mulatta).
J Med Primatol 1999;28(2):67-72.
Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J,
Beran M, Koller C, Giles FJ, Andreef M, Kornblau S, Giralt S,
Keating MJ, and Talpaz M. Treatment of Philadelphia
chromosome-positive early chronic phase chronic myelogenous
leukemia with daily doses of interferon alpha and low-dose cytarabine.
J Clin Oncol 1999;17(1):284-292.
Kornblau S, Thall PF, Estrov Z et al. The prognostic impact of
BCL2 protein expression in acute myelogenous leukemia varies with
cytogenetics. Clin Cancer Res 1999;5(7):1758-1766.
Kudelka AP, Verschraegen CF, Shen Y, Gonzalez de Leon C,
Edwards CL, Freedman S, Forman A, Gibbs HR, Mante R, Hord M,
Canetta R, Krakoff I, Kavanagh J. Long-term results and
pharmacokinetics of high-dose paclitaxel in patients with refractory
epithelial ovarian carcinoma. Int J Gynaecol
Cancer 1999;9:44-53.
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K,
Theriault FL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI,
McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical
course of breast cancer patients with complete pathologic primary
tumor and axillary lymph node response to doxorubicin-based
neoadjuvant chemotherapy. J Clin Oncol 1999;17(2):460-469.
Lopez-Guillermo A, Cabanillas F, McDonnel TI, McLaughlin P,
Smith TL, Pugh W, Hagemeister F, Rodriguez MA, Romaguera JE,
Younes A, Sarris AH, Preti HA, and Lee M-S. Correlation of Bcl-2
rearrangement with clinical characteristics and outcome in indolent
follicular lymphoma. Blood 1999;93(9):3081-3087.
Mielke CH Jr, Starr CM, Klock JC, Devereaux D, Mielke MR, Baker DE, Broemeling L, Wacksman M, White JR Jr, Oliver SA, ENs G, Gavin P, Dittman WA.
Direct measurement of unfractionated heparin using a biochemical assay.
Clin Appl Thromb Hemost 1999;5(4):267-276.
Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated
for early-stage breast cancer? A decision analysis. J Clin Oncol 1999;17(5):1465-1473.
Pratiwi R, Fletcher LM, Pyper WR, Do K-A, Crawford DH, Powell LW, Jazwinska EC. Linkage disequilibrium analysis
in Australian haemochromatosis patients indicates bipartite association with clinical expression. J Hepatol 1999;31(1):39-46.
Prosnitz LR, Maguire P, Anderson Jm, Scully SP, Harrelson JM, Jones EL, Dewhirst M, Samulski TV, Powers BE, Rosner GL,
Dodge RK, Layfield L, Clough R, Brizel DM. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy.
Int J Radiat Oncol Biol Phys 1999;45(4):941-949.
Przepiorka D, Khouri I, Thall PF, Mehra R, Lee M-S, Ippoliti C,
Giralt S, Gajewski J, van Besien K, Andersson B, Korbling M,
Deisseroth A, and Champlin R. Thiotepa, busulfan and
cyclophosphamide as a preparative regimen for allogeneic
transplantation for advanced chronic myelogenous leukemia. Bone
Marrow Transpl 1999;23:977-981.
Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT,
Mehra R, Korlbing M, Huh YO, Giralt S, Gajewski J, Donato M,
Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS,
Anderlini P, and Champlin R. Risk factors for acute graft-versus-host
disease after allogeneic blood stem cell transplantation.
Blood 1999;94(4):1465-1470.
Pusztai L, Asmar L, Smith TL, and Hortobagyi GN. Relapse after
complete response to anthracycline-based combination chemotherapy in
metastatic breast cancer. Breast Cancer Res Treat 1999;55(1):1-8.
Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN.
Results and long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose
doxorubicin-containing chemotherapy: a reference. Cancer 1999;85(1):104-111.
Rhee CH, Hess KR, Ruiz M, Yang Y, Jabbur J, Chen S,
Chenchik A, Fuller GN, and Zhang W. cDNA expression array reveals
heterogeneous gene expression in three glioblastoma cell lines.
Oncogene 1999;18:2711-2717.
Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry DA, Petros WP, Gilbert C,
Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors
for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy
with autologous stem-cell support. J Clin Oncol 1999;17(10):3064-3074.
Ryan PA, Do K-A, Kay BH. Spatial and temporal analysis of Ross River virus disease patterns at Maroochy Shire,
Australia: Association between human morbidity and mosquito (Diptera: Culicidae) abundance. J Med Entomol 1999;36(4):515-521.
Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR,
Myers JN, Hong Y-K, Yung WKA, and Steck PA. Differential expression
of MMAC-PTEN in glioblastoma multiforme: relationship to localization
and prognosis. Cancer Res 1999;59(8):1820-1824.
Sellin RV, Palmer JL, Taylor S, and Cooksley CC. Incidence of
breast carcinoma in women with thyroid cancer. Cancer 1999;85:190-197.
Shen Y, Cheng SC. Confidence bands for cumulative
incidence curves under the additive risk model. Biometrics 1999;55:1093-1100.
Shen Y, Fisher L. Statistical inference for self-designing
clinical trials with a one-sided hypothesis. Biometrics 1999:55:190-197.
Shen Y, Fleming TF. Assessing effects on long-term
survival after early termination of randomized trials. Lifetime Data
Anal 1999;5:55-66.
Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death.
Stat Med 1998;17(9):999-1015.
Shen Y, Zelen M. Estimation procedures for screening
programs: stable and nonstable disease models for multi-modality case
finding. Biometrika 1999;86:503-515.
Sinicrope F, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y,
and Frazier ML. Reduced expression of cyclooxygenase-2 proteins in
hereditary nonpolyposis colorectal cancers relative to sporadic
cancers. Am J Gastroenterol 1999;117:350-358.
Stallard N, Thall PF, and Whitehead J. Decision theoretic
designs for phase II clinical trials with multiple outcomes.
Biometrics 1999;55:971-977.
Staniswalis JG, Lee JJ, Nonparametric regression analyses of longitudinal data. J Am Stat Assoc 1998;
93:1403-1418.
Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM,
McLaughlin PW, Rodriguez, MA, Romaguera JE, Sarris AH, Younes A,
Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE,
Winn RJ, Genta RM, Graham DY, and Cabanillas FF. Antibiotic
treatment trial of gastric lymphoma of mucosa-associated lymphoid
tissue. An uncontrolled trial. Ann Int Med 1999;131:88-95.
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH,
Connors DG, El-Naggar A, Fossella F, Glisson BS, Hong WK, Khuri JM,
Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC,
Perez-Soler R, Pisters KMW, Putnam JB, et al. Adenovirus-mediated
p53 gene transfer in advanced non-small cell lung cancer. J
Natl Cancer Inst 1999;91(9):763-771.
Tan FK, Stivers DN, Arnett FC, Chakraborty R, Howard R, Reveille JD. HLA haplotypes and microsatellite polymorphisms in and around
the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis).
Tissue Antigens 1999;53(1):74-80.
Thall PF, Cheng SC. Treatment comparisons based on
two-dimensional safety and efficacy alternatives in oncology trials.
Biometrics 1999;55:746-753.
Thall PF, Estey EH, Sung H-G. A new statistical method
for dose-finding based on efficacy and toxicity in early phase
clinical trials. Invest New Drugs 1999;17(2):155-167.
Thall PF, Lee JJ, Tseng C-H, Estey E. Accrual
strategies for phase I trials with delayed patient outcome.
Stat Med 1999;18(10):1155-1169.
Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J,
O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ.
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Cancer 1999;86(7):1216-1230.
Treolar SA, Do K-A, O'Connor VM, O'Connor DT, Yeo MA, Martin NG. Predictors of hysterectomy: an Australian study.
Am J Obstet Gynecol 1999;180(4):945-954.
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP,
Prados MD, Levin VA, Yung WKA. Outcomes and prognostic factors
in recurrent glioma patients enrolled onto phase II clinical trials.
J Clin Oncol 1999;17(8):2572-2578.
Xu XC, Lee JS, Lee JJ, Morice RC, Liu X, Lippman SM, Hong WK,
and Lotan R. Nuclear retinoid receptor beta in bronchial epithelium
of smokers before and during chemoprevention. J Natl
Cancer Inst 1999;91(15):1317-1321.
Last updated: March 12, 2001
For questions concerning these pages, contact the
Department of
Biostatistics Webmaster.
|
|
